CR20110374A - Agente preparativo / terapéutico contra el cáncer - Google Patents

Agente preparativo / terapéutico contra el cáncer

Info

Publication number
CR20110374A
CR20110374A CR20110374A CR20110374A CR20110374A CR 20110374 A CR20110374 A CR 20110374A CR 20110374 A CR20110374 A CR 20110374A CR 20110374 A CR20110374 A CR 20110374A CR 20110374 A CR20110374 A CR 20110374A
Authority
CR
Costa Rica
Prior art keywords
against cancer
therapeutic against
androgen independent
preparatory agent
cancer
Prior art date
Application number
CR20110374A
Other languages
English (en)
Inventor
Hisanori Matsui
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42025816&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110374(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20110374A publication Critical patent/CR20110374A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se provee un agente preventivo/terapéutico para cáncer independiente de andrógenos. Un agente preventivo/terapéutico para cáncer independiente de andrógenos incluye un derivado de metastina y es particularmente útil como un agente preventivo/terapéutico para cáncer independiente de andrógenos, en particular, cáncer de próstata independiente de andrógenos.
CR20110374A 2008-12-29 2011-06-29 Agente preparativo / terapéutico contra el cáncer CR20110374A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20388708P 2008-12-29 2008-12-29

Publications (1)

Publication Number Publication Date
CR20110374A true CR20110374A (es) 2011-09-19

Family

ID=42025816

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110374A CR20110374A (es) 2008-12-29 2011-06-29 Agente preparativo / terapéutico contra el cáncer

Country Status (26)

Country Link
US (1) US20110312898A1 (es)
EP (1) EP2379053A1 (es)
JP (1) JP2012513982A (es)
KR (1) KR20110111420A (es)
CN (1) CN102333520B (es)
AR (1) AR074918A1 (es)
AU (1) AU2009334235A1 (es)
BR (1) BRPI0923663A2 (es)
CA (1) CA2748517A1 (es)
CL (1) CL2011001519A1 (es)
CO (1) CO6382105A2 (es)
CR (1) CR20110374A (es)
DO (1) DOP2011000163A (es)
EA (1) EA019738B1 (es)
EC (1) ECSP11011166A (es)
GE (1) GEP20146001B (es)
IL (1) IL212913A0 (es)
MA (1) MA32935B1 (es)
MX (1) MX2011006170A (es)
NZ (1) NZ593381A (es)
PE (1) PE20110939A1 (es)
TN (1) TN2011000250A1 (es)
TW (1) TW201029660A (es)
UY (1) UY32367A (es)
WO (1) WO2010076896A1 (es)
ZA (1) ZA201103627B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5700641B2 (ja) * 2008-04-30 2015-04-15 国立大学法人京都大学 メタスチン誘導体およびその用途
EA020865B1 (ru) * 2009-12-22 2015-02-27 Такеда Фармасьютикал Компани Лимитед Композиция с замедленным высвобождением
MX2012014265A (es) * 2010-06-25 2013-01-18 Takeda Pharmaceutical Formulacion de liberacion sostenida.
JP6253146B2 (ja) * 2014-02-04 2017-12-27 国立大学法人山口大学 新規なペプチド誘導体及びこれを含有する医薬
WO2016099232A2 (ru) * 2014-10-20 2016-06-23 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Фармацевтический состав лечебно-профилактического действия и способ его приготовления
TWI778979B (zh) 2016-09-30 2022-10-01 瑞士商麥歐文科學有限公司 治療女性不孕症之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241051A1 (en) * 2002-12-26 2006-10-26 Chieko Kitada Metastin derivatives and use thereof
US6800611B2 (en) * 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
ZA200610820B (en) * 2004-06-25 2008-08-27 Takeda Pharmaceutical Metastin derivatives and use thereof
RU2006145886A (ru) * 2004-06-25 2008-06-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные метастина и их применение
AR058584A1 (es) * 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos

Also Published As

Publication number Publication date
NZ593381A (en) 2013-01-25
AR074918A1 (es) 2011-02-23
EA201100882A1 (ru) 2011-12-30
CA2748517A1 (en) 2010-07-08
US20110312898A1 (en) 2011-12-22
CN102333520B (zh) 2013-11-06
TW201029660A (en) 2010-08-16
CL2011001519A1 (es) 2012-03-16
ZA201103627B (en) 2012-09-26
EP2379053A1 (en) 2011-10-26
BRPI0923663A2 (pt) 2016-01-19
UY32367A (es) 2010-07-30
CO6382105A2 (es) 2012-02-15
EA019738B1 (ru) 2014-05-30
IL212913A0 (en) 2011-07-31
AU2009334235A1 (en) 2010-07-08
DOP2011000163A (es) 2011-07-31
MX2011006170A (es) 2011-06-27
ECSP11011166A (es) 2011-07-29
TN2011000250A1 (en) 2012-12-17
JP2012513982A (ja) 2012-06-21
PE20110939A1 (es) 2012-01-19
CN102333520A (zh) 2012-01-25
MA32935B1 (fr) 2012-01-02
WO2010076896A1 (en) 2010-07-08
GEP20146001B (en) 2014-01-10
KR20110111420A (ko) 2011-10-11

Similar Documents

Publication Publication Date Title
CR20110374A (es) Agente preparativo / terapéutico contra el cáncer
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
UY31432A1 (es) Compuestos de diarilhidantoina
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
PH12014501639A1 (en) Pharmaceutical compositions and methods
CR20110553A (es) Terapia complementaria contra el cáncer
BRPI0924549A2 (pt) nano fotomedicamentos como alvo para terapia fotodinâmica do câncer
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
EA201290838A1 (ru) Конъюгаты пирролбензодиазепина направленного действия
CL2011002595A1 (es) Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
EA201171367A1 (ru) Винилиндазолильные соединения
GB201020860D0 (en) Disulfiram formulation and uses thereof
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
GT200900124A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
AR076849A1 (es) Composicion de tratamiento para el cabello.
MX2013002058A (es) Composicion de tratamiento para cabello.
CL2015000715A1 (es) Anti-androgenos para el tratamiento de cáncer prostatico no metastasico y resistente de castracion
ECSP14011792A (es) Inhibidores de iap
NZ606730A (en) Methods for treating antipsychotic-induced weight gain
EP2345415A4 (en) THERAPEUTIC / PROPHYLACTIC AGENT FOR PROSTATE CANCER
BRPI0916435A8 (pt) Composição útil para a prevenção ou a redução do avanço do câncer de próstata

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)